WallStSmart

Baidu Inc (BIDU)vsHaoxi Health Technology Limited Class A Ordinary Shares (HAO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Baidu Inc generates 302351% more annual revenue ($129.08B vs $42.68M). BIDU leads profitability with a 4.3% profit margin vs -6.5%. HAO trades at a lower P/E of 0.4x. BIDU earns a higher WallStSmart Score of 46/100 (D+).

BIDU

Hold

46

out of 100

Grade: D+

Growth: 2.7Profit: 4.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: 2.40

HAO

Hold

39

out of 100

Grade: F

Growth: 8.7Profit: 2.0Value: 6.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BIDU.

HAOFair Value (-1.6%)

Margin of Safety

-1.6%

Fair Value

$1.22

Current Price

$0.72

$0.49 premium

UndervaluedFair: $1.22Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIDU2 strengths · Avg: 9.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

PEG RatioValuation
0.728/10

Growing faster than its price suggests

HAO4 strengths · Avg: 10.0/10
P/E RatioValuation
0.4x10/10

Attractively priced relative to earnings

Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
41.2%10/10

Revenue surging 41.2% year-over-year

EPS GrowthGrowth
172.7%10/10

Earnings expanding 172.7% YoY

Areas to Watch

BIDU4 concerns · Avg: 3.0/10
Return on EquityProfitability
1.9%3/10

ROE of 1.9% — below average capital efficiency

Profit MarginProfitability
4.3%3/10

4.3% margin — thin

Operating MarginProfitability
4.5%3/10

Operating margin of 4.5%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

HAO4 concerns · Avg: 2.0/10
Market CapQuality
$65.98M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-16.0%2/10

ROE of -16.0% — below average capital efficiency

Free Cash FlowQuality
$-2.27M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-6.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : BIDU

The strongest argument for BIDU centers on Price/Book, PEG Ratio. PEG of 0.72 suggests the stock is reasonably priced for its growth.

Bull Case : HAO

The strongest argument for HAO centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 41.2% demonstrates continued momentum.

Bear Case : BIDU

The primary concerns for BIDU are Return on Equity, Profit Margin, Operating Margin. A P/E of 70.3x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.

Bear Case : HAO

The primary concerns for HAO are Market Cap, Return on Equity, Free Cash Flow.

Key Dynamics to Monitor

BIDU profiles as a value stock while HAO is a hypergrowth play — different risk/reward profiles.

BIDU carries more volatility with a beta of 0.43 — expect wider price swings.

HAO is growing revenue faster at 41.2% — sustainability is the question.

BIDU generates stronger free cash flow (88M), providing more financial flexibility.

Bottom Line

BIDU scores higher overall (46/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Baidu Inc

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · China

Baidu, Inc. provides Internet search services primarily in China. The company is headquartered in Beijing, China.

Haoxi Health Technology Limited Class A Ordinary Shares

COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA

Haoxi Health Technology Limited Class A Ordinary Shares is an innovative leader in the health technology sector, dedicated to transforming healthcare delivery through cutting-edge solutions. By leveraging advanced technologies such as artificial intelligence and data analytics, the company enhances diagnostic accuracy, treatment efficiency, and overall patient management. With a strong commitment to research and development, Haoxi is strategically positioned to harness emerging trends in healthcare technology, offering substantial growth potential for institutional investors seeking to capitalize on the evolving landscape.

Want to dig deeper into these stocks?